Ischemia-Modified Albumin (IMA) levels in ectopic pregnancy and early pregnancy loss

Niger J Clin Pract. 2022 Jul;25(7):975-978. doi: 10.4103/njcp.njcp_1464_21.

Abstract

Background: IMA is a novel marker to consider in ischemic conditions. The initial stages of pregnancy represent a physiological ischemic status. IMA levels may be changed when there is suspicion of early pregnancy complications because of increased oxidative stress.

Aim: We aimed to determine and compare IMA values in cases of ectopic and healthy pregnancies as well as early pregnancy loss.

Methods: This prospective case control study population (n = 91) consisted of early pregnancy loss (n = 28), ectopic pregnancy (n = 28), and an intracavitary early healthy pregnancy (n = 35). The serum IMA levels were compared in these groups.

Results: Demographic parameters were similar and there was no significant difference between the three groups in terms of serum IMA concentrations.

Conclusion: We suggested that IMA cannot be used clinically for the diagnosis and follow up of early pregnancy complications during the first five to six gestational weeks.

Keywords: Early pregnancy loss; IMA; ectopic pregnancy.

MeSH terms

  • Abortion, Spontaneous*
  • Biomarkers
  • Case-Control Studies
  • Female
  • Humans
  • Ischemia
  • Pregnancy
  • Pregnancy, Ectopic*
  • Serum Albumin
  • Serum Albumin, Human

Substances

  • Biomarkers
  • Serum Albumin
  • ischemia-modified albumin
  • Serum Albumin, Human